Supporting Information

Enhancing Antitumor Immunity with Stimulus-Responsive Mesoporous Silicon in Combination with Chemotherapy and Photothermal Therapy Shuai Chen^{c#}, Rui Huang^{a,b#}, Feiyang Shen^{a,b#}, Yijia Wu^{a,b}, Yao Lin^c, Xiaoyu Yang^{a,b}, Jianfeng Shen^{a, b, c *} and Yan Fang^{a,b*}

a. Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University
School of Medicine, Shanghai 200025, China

b. Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200025,

China

c. Institute of Translational Medicine, National Facility for Translational Medicine, Shanghai

Jiao Tong University, Shanghai 200240, China

* Correspondence should be addressed to Yan Fang (yanyan2021fang@sjtu.edu.cn)

[#] Shuai Chen, Rui Huang and Feiyang Shen contributed equally to this manuscript.

1. Synthesis of thiol functionalized HA (HA-SH)

200 mg HA (0.5 mmol) was dissolved in 30 mL PBS (pH = 7.4). Then, 287.55 mg EDCI (1.5 mmol) and 202.73 mg HOBt (1.5 mmol) were added to react with HA for 4 h to activate the carboxyl, 385.75 mg cystamine dihydrochloride (2.5 mmol) was added and stirred for 24 h at 25 °C. The above mixture was then dialyzed against deionised water at 25 °C for 24 h (MW cutoff: 8000–14000). Subsequently, the above solution's pH value was adjusted to 8-9 with 10 % NaOH (wt %), 385.63 mg DTT (2.5 mmol) was added to the solution, and stirred for 24 h. Then, the pH the resulting solution was adjusted to 3-4 with HCl, and the solution was dialyzed against deionised water at 25 °C. Yield: 177 mg (77 %). The chemical structure HA-SH was characterized by FT-IR and ¹H NMR (400 MHz).

2. Supplementary figures



Fig. S1 Synthesis route of HA-HS.





Fig. S3 ¹H NMR spectra of HA-SH.





Fig.S4 UV-Vis absorption spectrum of free DOX, MSN@PDA, DOX/MSN and DOX/MSN@PDA.

Fig. S5 Changes in Size Responsiveness of MSN@PDA-HA.



Fig.S6 Real-time temperature growth curves of MSN@PDA-HA and DOX/MSN@PDA-HA at various concentration irradiated with 808 nm laser (2.0 W cm⁻²).



Fig.S7 Cell viability of 4T1 cells measured by CCK-8 assay at 37 °C.



Fig.S8 Quantification of the cell apoptosis induced by indicated formulations after 24 h in 4T1 cells.



Fig.S9 Representative colony formation of 4T1 after different treatments.



Fig.S10 Quantification of colony formation of 4T1 after different treatments. Data are shown as mean \pm SD (n = 3, one-way ANOVA).



Fig.S11 Real-time temperature of the tumor after 12 hours of different treatments with 808nm laser irradiation for 3 minutes.



Fig.S12 Flow cytometry plots showing different groups of Treg cells in tumor (gated on CD4⁺ cells).



Fig.S13 Quantitative analysis of Treg cells in tumor after the mice received different treatments.



Fig.S14 Flow cytometry plots showing different groups of Treg cells in lymphoid nodes (gated on CD4⁺ cells).



Fig.S15 Quantitative analysis of Treg cells after the mice received different treatments.



Fig.S16 Evaluation of the percentages of Treg cells in spleen (gated on CD4⁺ cells).



Fig.S17 Quantitative analysis of Treg cells after the mice received different treatments.



Fig.S18 H&E staining images of major organs (heart, liver, spleen, and kidney) collected from various groups at the endpoint of the treatments (scale bar: $100 \ \mu m$).



Fig.S19 Main physiological indexes (AST, ALT, UREA and CREA) of mice after treatments of different groups (n = 3).